MBX Biosciences, Inc. Segment Reporting Other Item Amount
MBX Biosciences, Inc. (MBX) reported Segment Reporting Other Item Amount of $6.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentReportingOtherItemAmount · last filed 2026-08-06
- MBX Biosciences, Inc. segment reporting other item amount for the quarter ending 2026-06-30 was $6.11M, a 262.18% increase year-over-year.
- MBX Biosciences, Inc. segment reporting other item amount for the quarter ending 2026-03-31 was $5.04M, a 241.90% increase year-over-year.
- MBX Biosciences, Inc. segment reporting other item amount for the quarter ending 2025-12-31 was $2.30M, a 534.44% increase year-over-year.
- MBX Biosciences, Inc. segment reporting other item amount for the quarter ending 2025-09-30 was $2.35M, a 68.32% increase year-over-year.
- MBX Biosciences, Inc. segment reporting other item amount for fiscal 2025 was $7.81M, a 73.33% increase from fiscal 2024.
- MBX Biosciences, Inc. segment reporting other item amount for fiscal 2024 was $4.51M, a 11.86% increase from fiscal 2023.
- MBX Biosciences, Inc. segment reporting other item amount for fiscal 2023 was $4.03M.
| Period end | Segment Reporting Other Item Amount 3 month | Segment Reporting Other Item Amount 6 month | Segment Reporting Other Item Amount 9 month | Segment Reporting Other Item Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.11M 10-Q · filed 2026-08-06 | $11.15M 10-Q · filed 2026-08-06 | $13.46M derived: sum of 3 quarters · filed 2026-08-06 | $15.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.04M 10-Q · filed 2026-05-07 | $7.35M derived: sum of 2 quarters · filed 2026-05-07 | $9.69M derived: sum of 3 quarters · filed 2026-05-07 | $11.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.65M derived: sum of 2 quarters · filed 2026-03-12 | $6.34M derived: sum of 3 quarters · filed 2026-08-06 | $7.81M 10-K · filed 2026-03-12 |
| 2025-09-30 | $2.35M 10-Q · filed 2025-11-06 | $4.04M derived: sum of 2 quarters · filed 2026-08-06 | $5.51M 10-Q · filed 2025-11-06 | $5.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.69M 10-Q · filed 2026-08-06 | $3.16M 10-Q · filed 2026-08-06 | $3.52M derived: sum of 3 quarters · filed 2026-08-06 | $4.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.48M 10-Q · filed 2026-05-07 | $1.84M derived: sum of 2 quarters · filed 2026-05-07 | $3.23M derived: sum of 3 quarters · filed 2026-05-07 | $4.69M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $363.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.76M derived: sum of 2 quarters · filed 2026-03-12 | $3.22M derived: sum of 3 quarters · filed 2026-03-12 | $4.51M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.40M 10-Q · filed 2025-11-06 | $2.86M derived: sum of 2 quarters · filed 2025-11-06 | $4.14M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $1.46M 10-Q · filed 2025-08-07 | $2.75M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $1.29M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $4.03M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |